Catalent (NYSE: CTLT) reported Q4 EPS of $0.67, $0.07 better than the analyst estimate of $0.60. Revenue for the quarter came in at $685.3 million versus the consensus estimate of $690.49 million.

“Our financial performance for the fourth quarter was in line with our expectations and positions us well heading into fiscal year 2019,” said John Chiminski, Chair, President and Chief Executive Officer of Catalent, Inc. “We\'re excited to have closed another acquisition on August 14th -Juniper Pharmaceuticals- which adds to our spray drying capability and creates a European early-stage formulation and development center of excellence. The integration of both Juniper and our Bloomington biologics acquisition, which closed during the second quarter, is progressing according to plan. We\'re also very pleased to have strengthened our balance sheet by paying down $450 million of floating-rate term loan with the proceeds from our July 2018 equity offering. These strategic steps allow us to play a role in the continued consolidation of this fragmented industry."

GUIDANCE:

Catalent sees FY2019 revenue of $2.5-2.59 billion, versus the consensus of $2.47 billion.

For earnings history and earnings-related data on Catalent (CTLT) click here.